首页> 美国卫生研究院文献>Acta Bio Medica : Atenei Parmensis >Is the risk of contrast-induced nephropathy a real contraindication to perform intravenous contrast enhanced Computed Tomography for non-traumatic acute abdomen in Emergency Surgery Department?
【2h】

Is the risk of contrast-induced nephropathy a real contraindication to perform intravenous contrast enhanced Computed Tomography for non-traumatic acute abdomen in Emergency Surgery Department?

机译:急诊科对非创伤性急性腹部进行造影剂增强的计算机体层摄影术是造影剂引起的肾病的风险的真正禁忌症吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Contrast enhanced Computed Tomography (CCT) is the most used imaging test to investigate acute abdominal clinical conditions, because of its high sensitivity and specificity. It is mandatory to make a correct and prompt diagnosis when life threatening abdominal diseases as mesenteric ischemia are suspected. Contrast medium administration was linked to acute renal failure, therefore radiologist often prefer to perform CCT without contrast in patients needing to undergo the exam with increased serum creatinine. The aim of the review was to focus on the incidence of contrast induced nephropathy in patients presenting non-traumatic acute abdominal clinical conditions, who underwent CCT with intravenous contrast agent administration in emergency setting.Materials and Methods: The systematic review protocol was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocol (PRISMA-P). Quality of the evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Results: The strongest currently available evidence on the incidence of post-contrast acute kidney injury (AKI) following intravenous contrast agent administration consists in a meta-analysis of observational studies. Data extracted from meta-analyses demonstrate that, compared with non-contrast CT, CCT was not significantly associated with AKI. Moreover, the risk of AKI (RR=0.79; 95% confidence interval [CI]: 0.62, 1.02; P=.07), death (RR=0.95; 95% CI: 0.55, 1.67; P=.87), and dialysis (RR=0.88; 95% CI: 0.23, 3.43; P=.85) is similar, compared with the risk of AKI in the non-contrast medium group. Furthermore, intravenous low-osmolality iodinated contrast material is a nephrotoxic risk factor, but not in patients with a stable SCr level less than 1.5 mg/dL, therefore many factors other than contrast material could affect PC-AKI rates. Discussion and conclusions: The benefits of diagnostic information gained from contrast enhanced TC in assessing AA are fundamental in some clinical scenarios. The risk of contrast induced nephropathy (CIN) is negligible in patients with normal renal function but the incidence appears to rise to as high as 25% in patients with pre-existing renal impairment or in the presence of risk factors such as diabetes, advanced age, vascular disease and use of certain concurrent medications. The incidence of CIN/AKI after intravenous contrast administration is very low in general population. Radiologists and referring physicians should be familiar with the risk factors for renal disease, CIN and preventing measures. ()
机译:背景:对比增强计算机断层扫描(CCT)由于其高灵敏度和特异性,是研究急性腹部临床状况最常用的影像学检查。当怀疑由于肠系膜缺血而危及生命的腹部疾病时,必须做出正确,迅速的诊断。造影剂的给药与急性肾功能衰竭有关,因此对于需要接受血清肌酐增高检查的患者,放射线医师通常更愿意进行CCT检查而没有对比。审查的目的是着眼于非创伤性​​急性腹部临床病患的造影剂诱发的肾病的发生率,这些患者在紧急情况下接受静脉输注造影剂进行CCT。系统评价和荟萃分析协议(PRISMA-P)的首选报告项目。证据的质量将使用“建议评估,制定和评估分级”(GRADE)方法进行评估。结果:关于静脉注射造影剂后对比肾急性肾损伤(AKI)发生率的最强有力的现有证据是对观察性研究的荟萃分析。从荟萃分析中提取的数据表明,与非对比CT相比,CCT与AKI无关。此外,发生AKI的风险(RR = 0.79; 95%置信区间[CI]:0.62,1.02; P = .07),死亡(RR = 0.95; 95%CI:0.55、1.67; P = .87)和与非对比介质组的AKI风险相比,透析(RR = 0.88; 95%CI:0.23,3.43; P = .85)相似。此外,静脉内低渗碘化造影剂是一种肾毒性危险因素,但对于稳定的SCr水平低于1.5 mg / dL的患者而言并非如此,因此,除了造影剂以外,还有许多因素会影响PC-AKI发生率。讨论与结论:在某些临床情况下,从对比增强型TC获得的诊断信息对评估AA的益处至关重要。肾功能正常的患者造影剂诱发肾病(CIN)的风险可忽略不计,但在既往有肾功能不全或存在糖尿病,高龄等危险因素的患者中,发病率似乎高达25% ,血管疾病和某些并发药物的使用。在一般人群中,静脉内注射造影剂后CIN / AKI的发生率非常低。放射科医生和转诊医师应熟悉肾脏疾病,CIN和预防措施的危险因素。 ()

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号